as a fractional cmo i help transform science INTO PREDICTABLE, PATIENT-FIRST GROWTH FOR BIOPHARMA LEADERS
wE BRIDGE THE GAP BETWEEN SCIENCE AND PATIENTS - TRANSFORMING MARKETING CHAOS INTO A DISCIPLINED GROWTH SYSTEM THAT IS MEASURABLE, ACCOUNTABLE, AND ROI-POSITIVE
I help science-driven pharma and biopharma leaders translate complex innovations into clear, compelling messages that resonate with patients. By building patient-first marketing strategies—grounded in education, trust, and accessibility—I ensure their breakthrough treatments reach the people who need them most. My work connects the brilliance of the science with the everyday concerns of patients, creating marketing that not only drives adoption and growth but also builds confidence with stakeholder and prepares the company for a successful launch.
Interested in accelerated patient uptake?
Did You know?
Successful launches begin years before approval, with deep market research, segmentation, and competitive analysis. This ensures the launch addresses real patient and provider needs, anticipates barriers, and stands out in crowded markets. p360
The most successful launches rely on analytics to guide tactical choices: identifying prescribers, segmenting patients, refining messaging, and selecting channels. This results in precise targeting and improved ROI for launching assets. drugpatentwatch
Nearly 66% of drug launches miss pre-launch sales expectations, and about 40–50% still fail to meet commercial targets even among mid- and large-cap companies. Most struggling launches (80%) that underperform in the first 6–24 months rarely recover to meet projections over the long term. LinkedIn
Companies that deliver clear value messaging, combine digital engagement with traditional marketing, and rapidly adjust to competitive market dynamics are more likely to experience swift uptake and commercial success. p360
Launches often miss targets when companies don’t deeply understand the needs, behaviors, and pain points of target patients, prescribers, or payers. This can stem from limited market research, overreliance on regulatory approval, or late/insufficient engagement with stakeholders. deloitte